NCT02843204View on ClinicalTrials.gov

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

July 1, 2017

Study Completion Date

July 1, 2019

Conditions

Malignant Solid Tumour

Interventions

DRUG

Pembrolizumab

Patients received i.v. pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle, until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure

BIOLOGICAL

NK immunotherapy

Each treatment: about 10 billion cells in all, infusion in 3 times, i.v.

Trial Locations (1)

510665

Cancer Institute in Fuda Cancer Hospital, Guangzhou

All Listed Sponsors

collaborator

Shenzhen Hank Bioengineering Institute

OTHER

lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT02843204 - Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors | Biotech Hunter | Biotech Hunter